Gynecologic Oncology - Cervical Cancer | |
|---|---|
| Study Name | Principal Investigator |
| MK2870-020-00 – A Phase 3 Randomized, Active-Controlled, Open-Label, Multicenter Study to Compare the Efficacy and Safety of MK2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20). Read more. |
Sharyn Lewin, MD |
Gynecologic Oncology - Endometrial Cancer | |
| Study Name | Principal Investigator |
| GOG-3039 – A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced,
Recurrent or Metastatic Endometroid Endometrial Cancer. Read more. |
Sharyn Lewin, MD |
| MK2870-005-03 – A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy (MK2870-005/ENGOT-en-23/GOG-3095). Read more. |
Sharyn Lewin, MD |
| MK2870-033-03 – A Phase 3 Randomized, Open-label, Multicenter Study to Comparae the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29) Read more. |
Sharyn Lewin, MD |
Gynecologic Oncology - Ovarian Cancer | |
| Study Name | Principal Investigator |
| DS6000-109 – A Phase 2/3 Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Dose Optimization and Phase 3 Study of R-DXd versus Investigator’s Choice of Chemotherapy in Platinum resistant Ovarian Cancer). Read more. |
Sharyn Lewin, MD |
| GOG-3068 – A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary, Peritoneal, and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial – HOTT). Read more. |
Sharyn Lewin, MD |
| IMGN151-1001 – A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers. Read more. |
Sharyn Lewin, MD |
| GCT1184-02 – A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer. Read more. |
Sharyn Lewin, MD |
